

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

**FINANCIAL INFORMATION OF
CSPC INNOVATION PHARMACEUTICAL CO., LTD.
FOR THE YEAR ENDED 31 DECEMBER 2025**

In compliance with the relevant requirements of Shenzhen Stock Exchange, CSPC Innovation Pharmaceutical Co., Ltd. (“**CSPC Innovation**”), a subsidiary of CSPC Pharmaceutical Group Limited (the “**Company**”) listed on the ChiNext Market of Shenzhen Stock Exchange (Stock Code: 300765), published its annual report for the year ended 31 December 2025 (the “**2025 Annual Report**”) on 16 March 2026 on the information disclosure webpage of Shenzhen Stock Exchange’s website at <http://www.szse.cn/disclosure/listed/notice/index.html>. CSPC Innovation’s financial information was prepared in accordance with the China Accounting Standards for Business Enterprises.

Set out in the appendices to this announcement (the “**Appendices**”) is the principal financial data of CSPC Innovation extracted from the 2025 Annual Report prepared in Chinese. In case of any inconsistency between the Chinese version and the English version, the Chinese version shall prevail.

Shareholders and potential investors of the Company are reminded that the financial information of CSPC Innovation in the 2025 Annual Report and in the Appendices are consolidated financial information of CSPC Innovation for the year ended 31 December 2025, rather than that of the Company. They should exercise caution when dealing in the securities of the Company.

By Order of the Board
CSPC Pharmaceutical Group Limited
CAI Dong Chen
Chairman

Hong Kong, 16 March 2026

As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Dr. CAI Lei, Mr. WEI Qingjie, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin, Mr. CHEN Weiping, Mr. QU Zhiyong and Mr. ZHANG Yiwei as Executive Directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as Independent Non-executive Directors.

APPENDIX I

KEY ACCOUNTING DATA AND FINANCIAL INDICATORS

Currency: RMB

	2025	2024	Increase/ decrease of the year compared with the last year	2023
Operating revenue (Yuan)	2,157,680,212.70	1,980,753,001.94	8.93%	2,538,713,472.31
Net profit attributable to shareholders of the listed company (Yuan)	-241,125,740.52	53,726,318.63	-548.80%	434,435,597.81
Net profit attributable to shareholders of the listed company after deducting non-recurring profit or loss (Yuan)	-294,413,898.37	42,341,882.94	-795.33%	743,672,985.61
Net cash flow generated from operating activities (Yuan)	-195,692,571.33	-1,235,054,404.22	84.16%	721,139,552.49
Basic earnings per share (Yuan/share)	-0.1731	0.0384	-550.78%	0.3110
Diluted earnings per share (Yuan/share)	-0.1731	0.0384	-550.78%	0.3110
Weighted average return on net assets	-6.96%	1.10%	-8.06%	9.36%
	At the end of 2025	At the end of 2024	Increase/ decrease compared with the end of the last year	At the end of 2023
Total assets (Yuan)	6,276,311,291.82	6,022,115,755.32	4.22%	7,472,208,452.03
Net assets attributable to shareholders of the listed company (Yuan)	2,667,343,683.63	3,730,544,275.59	-28.50%	5,280,823,722.20

APPENDIX II

NON-RECURRING PROFIT OR LOSS ITEMS AND AMOUNTS

Unit: Yuan Currency: RMB

Items	Amounts for 2025	Amounts for 2024	Amounts for 2023
Gain/loss from disposal of non-current assets (including the part offset with the provision for impairment of assets)	2,782,751.39	545,287.31	-1,819,411.71
Government grants recognised in profit or loss of current period (excluding those closely related to the company's normal operating business, complied with national policies and regulations, granted according to determined standards, and continuously affecting the Company's gain/loss)	77,378,710.61	15,980,013.00	13,821,721.77
Profit or loss from changes in fair value of financial assets and financial liabilities held by non-financial enterprises, and profit or loss from disposal of financial assets and financial liabilities, other than effective hedging activities related to normal business operations of the Company	17,969,533.96	1,733,768.57	
Net current profit or loss of subsidiaries from the beginning of the period to the consolidation date arising from consolidation of companies under common control			-629,650,304.85
Other non-operating income and expenses other than the above items	-6,124,408.09	-2,988,904.19	2,143,922.54
Less: Impacts of income tax	2,382,755.24	376,600.30	2,352,729.90
Impact of minority interests (after tax)	36,335,674.78	3,509,128.70	-308,619,414.35
Total	53,288,157.85	11,384,435.69	-309,237,387.80

APPENDIX III

SIGNIFICANT CHANGES IN ASSETS COMPONENTS

Unit: Yuan Currency: RMB

	End of 2025		Beginning of 2025		Changes	Description on significant changes
	Amount	Percentage of total asset	Amount	Percentage of total asset		
Cash and bank balances	772,169,026.93	12.30%	872,081,872.91	14.48%	-2.18%	Mainly due to the fact that the company purchased large time deposit certificate and Megalith Biopharma made R&D payments during the reporting period.
Trade receivables	441,330,765.53	7.03%	314,097,126.88	5.22%	1.81%	Mainly due to the increase in revenue from the company's biopharmaceutical products during the reporting period.
Inventories	497,803,175.22	7.93%	398,668,570.98	6.62%	1.31%	Mainly due to the expansion of the biopharmaceutical business, leading to an increase in material reserves required for R&D activities, as well as an increase in the inventory of biopharmaceutical products.
Investment property	18,743,496.08	0.30%			0.30%	Mainly due to the completion and transfer of the human milk oligosaccharides project of the company during the reporting period.
Long-term equity investments	259,224,939.15	4.13%	264,448,153.62	4.39%	-0.26%	No significant change.
Fixed assets	2,116,527,618.55	33.72%	2,046,598,550.77	33.98%	-0.26%	No significant change.
Construction in progress	681,253,487.43	10.85%	620,225,532.01	10.30%	0.55%	No significant change.
Right-of-use assets	2,450,251.41	0.04%	1,328,072.18	0.02%	0.02%	No significant change.
Short-term borrowings	3,204,584.27	0.05%			0.05%	Mainly due to the discounting of bills receivables before maturity.
Contract liabilities	26,085,436.73	0.42%	18,683,904.44	0.31%	0.11%	No significant change.
Lease liabilities	1,661,791.85	0.03%			0.03%	No significant change.